SCHEMBL4656458

SCHEMBL4656458

COC1=CCC(C=CC(=O)c2ccc(O)cc2O)C=C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
CYP3A4 P08684 6/20 0.47
MAPT P10636 5/20 0.47
MAPK1 P28482 5/20 0.47
ABCG2 Q9UNQ0 4/20 0.47
HPGD P15428 4/20 0.47
ALOX15 P16050 4/20 0.47
TP53 P04637 3/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
HSD17B10 Q99714 3/20 0.47
TDP1 Q9NUW8 4/20 0.46
NFKB1 P19838 4/20 0.46
NFKB2 Q00653 3/20 0.46
RELA Q04206 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NR1H4 Q96RI1 2/20 0.46
ALOX12 P18054 1/20 0.46
CTSL P07711 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27676946 0.90 CAPN1 (0.51) MEN1KMT2ACYP3A4MAPTMAPK1
SCHEMBL2023110 0.84 CYP3A4 (0.47) MEN1KMT2ACYP3A4MAPTMAPK1
SCHEMBL4655610 0.81 ABCG2 (0.52) MEN1KMT2ACYP3A4MAPTMAPK1
SCHEMBL5084410 0.81 MAOA (0.45) MEN1KMT2ACYP3A4MAPTMAPK1
SCHEMBL8115829 0.80 AURKA (0.40) CYP3A4ABCG2NFKB1NFKB2RELA
SCHEMBL15467475 0.79 MEN1 (0.47) MEN1KMT2ACYP3A4MAPTMAPK1
SCHEMBL2023335 0.79 MEN1 (0.47) MEN1KMT2ACYP3A4MAPTMAPK1
SCHEMBL30254953 0.77 MAPT (0.42) MEN1KMT2ACYP3A4MAPTABCG2
SCHEMBL29267639 0.76 AURKA (0.50) MEN1KMT2ACYP3A4MAPTABCG2
SCHEMBL5127011 0.76 ALDH1A1 (0.34) MAPK1HPGDALOX15ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045522-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-02-09 US claimed
WO-2021113473-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2021-06-10 WO claimed
EP-1996212-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS Rutgers, The State University of New Jersey (US) 2008-12-03 EP claimed
WO-2007109217-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO claimed
US-20070224301-A1 Compounds from an extract of Artemisia and methods for treating disorders RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-09-27 US claimed
US-20230045522-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-02-09 US disclosed
WO-2021113473-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2021-06-10 WO disclosed
US-20140135359-A1 METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES MARTINEAU LOUIS C (CA) 2014-05-15 US disclosed
EP-1996212-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS Rutgers, The State University of New Jersey (US) 2008-12-03 EP disclosed
EP-1996212-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS Rutgers, The State University of New Jersey (US) 2008-12-03 EP disclosed
WO-2007109217-A3 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS RUTGERS THE STATES UNIVERSITY (US) 2008-01-17 WO disclosed
WO-2007109217-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO disclosed
WO-2007109217-A2 COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (US) 2007-09-27 WO disclosed
US-20070224301-A1 Compounds from an extract of Artemisia and methods for treating disorders RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-09-27 US disclosed
US-20070224301-A1 Compounds from an extract of Artemisia and methods for treating disorders RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070224301-A1 Compounds from an extract of Artemisia and methods for treating disorders PDK2, PCK2, DUSP2 MEN1 3925/4885KMT2A 1873/4885CYP3A4 2330/4885
US-20140135359-A1 METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES UQCRC2, UQCRC1, TIMM50 MEN1 1092/4885KMT2A 3551/4885CYP3A4 1091/4885
US-20230045522-A1 COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS GCKR, G6PC1, GPR119 MEN1 1345/4885KMT2A 3878/4885CYP3A4 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.